Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Daclizumab.

Marcus Mottershead1, James Neuberger

  • 1Queen Elizabeth Hospital, Liver Unit, Birmingham, B15 2TH, UK.

Expert Opinion on Biological Therapy
|October 6, 2007
PubMed
Summary
This summary is machine-generated.

Daclizumab, an IL-2 receptor antibody, effectively reduces acute rejection in organ transplant induction therapy. This immunosuppressive agent is well-tolerated and does not increase infection or PTLD rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An international multidisciplinary consensus statement on laparoscopic liver biopsy.

Cell reports. Medicine·2026
Same author

Toward Reducing Inequity in Transplantation of the Socioeconomic Disadvantaged: A Glimmer of Hope?

Transplantation·2026
Same author

Guidelines from the expert advisory committee on the Safety of Blood, Tissues and Organs (SaBTO) on patient consent and shared decision-making for blood transfusion.

British journal of haematology·2025
Same author

What price for increasing blood safety?

Lancet (London, England)·2025
Same author

Strong or Weak Consent in Medical Law? Identifying the Values Protected in Transplantation Medicine in Europe.

European journal of health law·2025
Same author

We should implement electronic blood management systems across the UK to improve blood transfusion safety.

BMJ (Clinical research ed.)·2025
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Daclizumab is a humanized monoclonal antibody targeting the IL-2 receptor on activated lymphocytes.
  • It inhibits Interleukin-2 (IL-2) production, a key cytokine in immune responses.

Purpose of the Study:

  • To evaluate the efficacy and safety of daclizumab as induction therapy in solid organ transplantation.
  • To assess its role in managing high-risk transplant patients requiring modified immunosuppression.

Main Methods:

  • Daclizumab administered in 2-dose or 5-dose regimens.
  • Used in conjunction with standard immunosuppressive agents for solid organ transplantation.
  • Clinical outcomes including acute rejection, infection, and PTLD were monitored.

Related Experiment Videos

Main Results:

  • Significantly reduced incidence of acute rejection in transplant recipients.
  • No increase observed in rates of infection or post-transplant lymphoproliferative disorders (PTLD).
  • Generally well-tolerated in both adult and pediatric populations, with no additional monitoring required.

Conclusions:

  • Daclizumab is an effective induction therapy for solid organ transplantation, particularly in high-risk patients.
  • It offers a favorable safety profile, reducing rejection without compromising infection control.
  • Limited success reported in non-transplant immune-mediated diseases.